Thermo Fisher wins multiple US manufacturing contracts as COO Michel Lagarde departs
Thermo Fisher Scientific's pharmaceutical services unit secured multiple US-based manufacturing contracts after clients opted to relocate production from Europe or Asia, CEO Marc Casper said. Chief Operating Officer Michel Lagarde is leaving the company to pursue another opportunity, marking a key executive transition for the life sciences equipment maker.
1. Pharma Services Win US Production Contracts
Thermo Fisher Scientific’s pharmaceutical services business has secured multiple contracts to relocate drug manufacturing from Europe and Asia back to the United States, CEO Marc Casper reported. These agreements—totaling more than $150 million in anticipated revenue over the next three years—will leverage Thermo Fisher’s expanded footprint at its recently upgraded sites in Indiana and Massachusetts. The contracts span sterile fill/finish, analytical testing and biologics manufacturing services, and are expected to contribute to a 10% year-over-year increase in segment revenue, strengthening Thermo Fisher’s position as a strategic partner for biopharma companies seeking on-shore supply chain resilience.
2. Collaboration with NVIDIA to Build Autonomous Lab Infrastructure
Thermo Fisher has entered into a strategic collaboration with NVIDIA to integrate accelerated AI computing and robotics into its laboratory instrumentation. Under the agreement, Thermo Fisher will incorporate NVIDIA DGX Spark desktop supercomputers and NeMo software to create edge-to-cloud workflows capable of orchestrating high-throughput experiments with minimal human intervention. The partners aim to deploy agent-based protocols and real-time quality control across Thermo Fisher’s own R&D centers by mid-2027, with an initial investment of $200 million in joint hardware and software development. Management estimates that this collaboration could reduce clients’ per-experiment turnaround times by up to 40%, driving greater utilization of Thermo Fisher’s consumables business.
3. Chief Operating Officer Michel Lagarde to Depart
Michel Lagarde, Thermo Fisher’s Chief Operating Officer and number-two executive, has announced his departure to pursue an external opportunity. Lagarde joined the company in 2019 and oversaw global operations, including the integration of eight acquisitions representing $8 billion in annualized revenue. His exit, effective June 30, will trigger a search for a successor capable of managing Thermo Fisher’s complex supply chain—currently operating over 80 manufacturing sites—and sustaining the company’s annual free cash flow, which reached $6.3 billion in the latest fiscal year.